Zepbound for sleep apnea: what SURMOUNT-OSA actually showed

SURMOUNT-OSA tested tirzepatide in adults with obesity and moderate-to-severe OSA, including people who used CPAP and people who did not. The primary measure was the apnea-hypopnea index, the number of times per hour breathing stops or shallows during sleep, which defines OSA severity.

Tirzepatide lowered AHI by roughly 25 to 30 events per hour on average, a large reduction, and a substantial share of participants improved enough to drop below the moderate-to-severe threshold, with some meeting criteria for disease resolution. Weight loss tracked the tirzepatide obesity trials.

For weight-linked OSA, reducing fat around the upper airway and abdomen makes the airway less likely to collapse and eases the mechanical load on breathing during sleep. That is the pathway here: the sleep benefit follows the weight benefit rather than acting on the airway directly.

This is also the honest limit. OSA has other contributors (anatomy, age, other factors), so weight loss helps most where weight is the main driver, and results vary from person to person.

Not automatically. In the trial, tirzepatide helped whether or not people used CPAP, and improvement was real, but a lower AHI on a drug does not by itself mean CPAP can be stopped. That decision needs a repeat sleep study and your sleep clinician's judgment.

The realistic picture for many people is combination and then reassessment: keep effective therapy in place, lose weight on tirzepatide, and let a follow-up study show whether your CPAP settings or need have changed. Do not stop CPAP on your own.

Zepbound for OSA carries the same tirzepatide cautions as for weight: the class GI effects during titration, pancreatitis and gallbladder vigilance, the thyroid C-cell exclusion for a personal or family history of medullary thyroid cancer or MEN2, reduced oral-contraceptive effectiveness, and stopping before a planned pregnancy.

It is approved for OSA specifically in adults with obesity; it is not a treatment for sleep apnea without that context, and untreated moderate-to-severe OSA is dangerous, so nothing here is a reason to delay evaluation or abandon current therapy.

If you have obesity and moderate-to-severe OSA, this is a conversation to have with both your prescriber and your sleep clinician, coordinated rather than separate. The weight-management playbook is the same as for any tirzepatide user: protein, training to protect muscle, hydration, and steady tracking.

Logging your dose, weight, and sleep alongside your CPAP data gives that follow-up sleep study real context, so any change to your OSA treatment is a documented decision rather than a guess.